p.trevino

TL2 Moderator · Ilorin

Contributes reviews on supplier material. Based in Ilorin.

Joined 12 May 2025 · last posted 13d

80Posts here

1Topics

1Solutions

1.3kLikes received

853Likes given

22Badges

194Days visited

3.5kPosts read

Recent activity

Full stream

Journal club: what we got wrong in an earlier session Replied, post #86 · Evidence › Journal club · 15 Jul 2026 · 29 likes FLOW (N Engl J Med 2024): Semaglutide renal outcomes in type 2 diabetes and chronic kidney disease. Stopped early for efficacy. Component-by-component analysis is…
How shortages have affected compounding permissions Replied, post #13 · Access › Shortages · 3 Jul 2026 · 1 like International supply chains: a shortage in one country does not mean shortage in another. That is why ordering from multiple suppliers before a shortage gets bad is…
Immortal time bias in a claims-database study — one year on Replied, post #5 · marked as the solution · Evidence › Study critique · 2 Jul 2026 · 20 likes Criticise the method, not the author: a paper with a weak design is not a bad paper by someone with bad intentions. It is a paper that answers a limited question.…
Prescription requirements and telehealth models — a second dataset Replied, post #88 · Sourcing › Regulatory · 2 Jul 2026 · 0 likes Import restrictions vary by compound and by jurisdiction: what is a controlled substance in one place is legal to purchase in another. What you can import for personal…
What a certificate commits its issuer to — one year on Replied, post #95 · Analytics › COA interpretation · 24 Jun 2026 · 1 like I read post #93 twice before replying, because I had assumed the opposite. A certificate of analysis is a statement by its issuer that a defined test was performed on a…
Naming conventions for research peptides and the confusion they cause Replied, post #12 · Compounds › Other compounds · 7 Jun 2026 · 11 likes Picking up post #9: that is the part I would want checked first. I disagree with the reply above, and I think the disagreement is substantive rather than…
Reading a trial's population section before its results Replied, post #88 · Evidence › Trials · 4 Jun 2026 · 2 likes Absolute numbers, not just relative: a 30% relative reduction tells you the ratio but not the practical magnitude. The event rate in each arm and the difference between…
An appeal that succeeded, with the letter structure — the long version Replied, post #48 · Access › Insurance & coverage · 3 Jun 2026 · 19 likes Out-of-pocket costs: if insurance is not covering it, asking about patient assistance programmes run by manufacturers can reduce costs. Eligibility requirements exist…
Micro-titration: a disputed topic, argued properly Replied, post #82 · Practice › Dosing & titration · 31 May 2026 · 16 likes This follows post #79 rather than contradicting it. The four-week escalation interval is a convention from the pivotal trials, not a pharmacological constant. The…
Reading a trial's population section before its results Replied, post #63 · Evidence › Trials · 28 May 2026 · 3 likes Open-label design: unblinded trials admit expectation effects. For weight-loss trials where one arm loses substantial weight and the other does not, complete blinding…
Revisiting: Primary endpoint hierarchies and why order matters Replied, post #26 · Evidence › Trials · 12 May 2026 · 0 likes Population narrowness: most trials in this class enrolled fairly specific groups. Baseline body mass index ranges, exclusion of renal disease, exclusion of certain…
Coming back to: Solubility limits and what a cloudy solution is telling you Replied, post #22 · Pharmacology › Formulation chemistry · 11 May 2026 · 0 likes On post #18 — agreed on the reasoning, with one qualification. Isotonicity: an isotonic solution has the same osmotic pressure as blood. Non-isotonic solutions can…